Study S001170

GLP-RA , DIABETIC , NON-DIABETIC , BMI ,TYG-index , HDL-C

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol, Statistical Analysis Plan, and Informed Consent Form (PDF)

Registration

Registration: NCT07820111
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 159
Start: 2025-10-18
Primary completion: 2026-03-17
Lead sponsor: Zagazig University
Conditions: Obese Diabetics; Obese Non Diabetic
Interventions: DRUG:Dulaglutide 1.5 MG/ML; DRUG:Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution; DRUG:Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician; DRUG:Dulaglutide 0.75mg subcutaneous injection; DRUG:Semaglutide 1.0 mg; DRUG:Tirzepatide (Flexible titration)
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

change in body weight at 3 and 6 months [6-MONTH STUDY PERIOD]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.